IL2 and systemic lupus erythematosus: The findings of this review suggested that biomarker improvement and attenuation by low-dose IL2 therapy in patients with SLE was consistently evident, while the same effect was not observed for RA patients treated with low-dose IL2 therapy; however, this may be due to limited articles that study the effects of low-dose IL2 therapy on RA biomarkers.